|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions decreases phosphorylation
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of AKT1 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of AKT1 protein]
|
CTD |
PMID:25053825 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions decreases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased expression of BCL2 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased expression of BCL2 protein]
|
CTD |
PMID:25053825 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l11
|
Bcl2-like 11
|
multiple interactions increases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in increased expression of BCL2L11 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein]
|
CTD |
PMID:25053825 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases cleavage
|
ISO
|
quizartinib affects the reaction [RGFP966 results in increased cleavage of CASP3 protein]; quizartinib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; RGFP966 affects the reaction [quizartinib results in increased cleavage of CASP3 protein]; romidepsin promotes the reaction [quizartinib results in increased cleavage of CASP3 protein]
|
CTD |
PMID:34665271 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cdk4
|
cyclin-dependent kinase 4
|
multiple interactions decreases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased expression of CDK4 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK4 protein]
|
CTD |
PMID:25053825 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163
|
|
G
|
Cdk6
|
cyclin-dependent kinase 6
|
multiple interactions decreases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased expression of CDK6 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased expression of CDK6 protein]
|
CTD |
PMID:25053825 |
|
NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions increases expression decreases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in increased expression of CDKN1A protein]; quizartinib inhibits the reaction [RGFP966 results in increased expression of CDKN1A protein]; quizartinib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein] quizartinib results in decreased expression of CDKN1A protein
|
CTD |
PMID:25053825 PMID:34665271 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Chek1
|
checkpoint kinase 1
|
decreases expression multiple interactions
|
ISO
|
quizartinib results in decreased expression of CHEK1 protein quizartinib promotes the reaction [RGFP966 results in decreased expression of CHEK1 protein]; quizartinib results in decreased expression of and results in increased phosphorylation of CHEK1 protein; RGFP966 promotes the reaction [quizartinib results in decreased expression of CHEK1 protein]; romidepsin promotes the reaction [quizartinib results in decreased expression of and results in increased phosphorylation of CHEK1 protein]
|
CTD |
PMID:34665271 |
|
NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359
|
|
G
|
Ctsa
|
cathepsin A
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSA protein
|
CTD |
PMID:30821613 |
|
NCBI chr 3:173,988,443...173,994,320
Ensembl chr 3:173,988,460...173,995,539
|
|
G
|
Ctsb
|
cathepsin B
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSB protein
|
CTD |
PMID:30821613 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478
|
|
G
|
Ctsd
|
cathepsin D
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSD protein
|
CTD |
PMID:30821613 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821
|
|
G
|
Ddx3x
|
DEAD-box helicase 3, X-linked
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein; [quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein; aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein]; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein]; leupeptin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein]
|
CTD |
PMID:30821613 |
|
NCBI chr X:12,152,346...12,165,983
Ensembl chr X:12,152,346...12,165,983
|
|
G
|
Eif4a1
|
eukaryotic translation initiation factor 4A1
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein; [quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein; aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein]; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein]; leupeptin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein]
|
CTD |
PMID:30821613 |
|
NCBI chr10:54,883,093...54,888,602
Ensembl chr10:54,883,093...54,888,602
|
|
G
|
Eif4h
|
eukaryotic translation initiation factor 4H
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein; [quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein; aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein]; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein]; leupeptin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein]
|
CTD |
PMID:30821613 |
|
NCBI chr12:27,719,527...27,736,350
Ensembl chr12:27,719,321...27,736,346
|
|
G
|
Flt3
|
Fms related receptor tyrosine kinase 3
|
multiple interactions decreases phosphorylation
|
ISO
|
quizartinib affects the reaction [RGFP966 results in decreased expression of and results in decreased phosphorylation of FLT3 protein alternative form]; quizartinib promotes the reaction [romidepsin results in decreased phosphorylation of FLT3 protein alternative form]; RGFP966 affects the reaction [quizartinib results in decreased phosphorylation of FLT3 protein alternative form]; romidepsin promotes the reaction [quizartinib results in decreased phosphorylation of FLT3 protein alternative form]
|
CTD |
PMID:34665271 |
|
NCBI chr12:12,660,035...12,735,584
Ensembl chr12:12,659,946...12,735,581
|
|
G
|
H2ax
|
H2A.X variant histone
|
multiple interactions increases phosphorylation
|
ISO
|
quizartinib affects the reaction [RGFP966 results in increased phosphorylation of H2AX protein]; quizartinib promotes the reaction [romidepsin results in increased phosphorylation of H2AX protein]; RGFP966 affects the reaction [quizartinib results in increased phosphorylation of H2AX protein]; romidepsin promotes the reaction [quizartinib results in increased phosphorylation of H2AX protein]
|
CTD |
PMID:34665271 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
H3f4
|
H3.4 histone, cluster member
|
multiple interactions
|
ISO
|
quizartinib promotes the reaction [romidepsin results in increased acetylation of H3-4 protein]
|
CTD |
PMID:34665271 |
|
NCBI chr10:44,240,282...44,240,842
|
|
G
|
Hexim1
|
HEXIM P-TEFb complex subunit 1
|
multiple interactions
|
ISO
|
quizartinib inhibits the reaction [(+)-JQ1 compound results in increased expression of HEXIM1 protein]
|
CTD |
PMID:25053825 |
|
NCBI chr10:88,562,889...88,565,001
Ensembl chr10:88,560,519...88,580,000
|
|
G
|
Hist1h4m
|
histone cluster 1, H4m
|
multiple interactions
|
ISO
|
quizartinib promotes the reaction [RGFP966 results in increased acetylation of H4C1 protein]
|
CTD |
PMID:34665271 |
|
NCBI chr17:47,393,764...47,394,168
Ensembl chr17:47,393,603...47,453,972 Ensembl chr17:47,393,603...47,453,972 Ensembl chr 4:47,393,603...47,453,972 Ensembl chr17:47,393,603...47,453,972 Ensembl chr17:47,393,603...47,453,972
|
|
G
|
Hk2
|
hexokinase 2
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein]
|
CTD |
PMID:30821613 |
|
NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275
|
|
G
|
Hspa8
|
heat shock protein family A (Hsp70) member 8
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HSPA8 protein alternative form
|
CTD |
PMID:30821613 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372
|
|
G
|
Lamp2
|
lysosomal-associated membrane protein 2
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein; [quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein alternative form; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein]
|
CTD |
PMID:30821613 |
|
NCBI chr X:122,038,734...122,087,745
Ensembl chr X:121,922,187...122,087,675
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions decreases phosphorylation
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of MAPK1 protein]; quizartinib affects the reaction [RGFP966 results in decreased phosphorylation of MAPK1 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK1 protein]; quizartinib promotes the reaction [romidepsin results in decreased phosphorylation of MAPK1 protein]; RGFP966 affects the reaction [quizartinib results in decreased phosphorylation of MAPK1 protein]; romidepsin promotes the reaction [quizartinib results in decreased phosphorylation of MAPK1 protein]
|
CTD |
PMID:25053825 PMID:34665271 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions decreases phosphorylation
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of MAPK3 protein]; quizartinib affects the reaction [RGFP966 results in decreased phosphorylation of MAPK3 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of MAPK3 protein]; quizartinib promotes the reaction [romidepsin results in decreased phosphorylation of MAPK3 protein]; RGFP966 affects the reaction [quizartinib results in decreased phosphorylation of MAPK3 protein]; romidepsin promotes the reaction [quizartinib results in decreased phosphorylation of MAPK3 protein]
|
CTD |
PMID:25053825 PMID:34665271 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions decreases expression
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased expression of MYC protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]
|
CTD |
PMID:25053825 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein]
|
CTD |
PMID:30821613 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions increases cleavage
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in increased cleavage of PARP1 protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in increased cleavage of PARP1 protein]
|
CTD |
PMID:25053825 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Rad51
|
RAD51 recombinase
|
decreases expression multiple interactions
|
ISO
|
quizartinib results in decreased expression of RAD51 protein quizartinib promotes the reaction [romidepsin results in decreased expression of RAD51 protein]; romidepsin promotes the reaction [quizartinib results in decreased expression of RAD51 protein]
|
CTD |
PMID:34665271 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
G
|
Rpa2
|
replication protein A2
|
multiple interactions increases phosphorylation
|
ISO
|
quizartinib affects the reaction [RGFP966 results in increased phosphorylation of RPA2 protein]; RGFP966 affects the reaction [quizartinib results in increased phosphorylation of RPA2 protein]
|
CTD |
PMID:34665271 |
|
NCBI chr 5:150,260,668...150,271,329
Ensembl chr 5:150,260,723...150,271,546
|
|
G
|
Stat5a
|
signal transducer and activator of transcription 5A
|
multiple interactions decreases phosphorylation
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of STAT5A protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5A protein]
|
CTD |
PMID:25053825 |
|
NCBI chr10:86,285,859...86,310,187
Ensembl chr10:86,285,547...86,310,184
|
|
G
|
Stat5b
|
signal transducer and activator of transcription 5B
|
multiple interactions decreases phosphorylation
|
ISO
|
(+)-JQ1 compound promotes the reaction [quizartinib results in decreased phosphorylation of STAT5B protein]; quizartinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of STAT5B protein]
|
CTD |
PMID:25053825 |
|
NCBI chr10:86,205,148...86,276,178
Ensembl chr10:86,207,293...86,275,990
|
|
G
|
Tp53
|
tumor protein p53
|
decreases expression multiple interactions
|
ISO
|
quizartinib results in decreased expression of TP53 protein RGFP966 promotes the reaction [quizartinib results in decreased expression of TP53 protein]; romidepsin promotes the reaction [quizartinib results in decreased expression of TP53 protein]
|
CTD |
PMID:34665271 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tyms
|
thymidylate synthetase
|
decreases expression
|
ISO
|
quizartinib results in decreased expression of TYMS protein
|
CTD |
PMID:34665271 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097
|
|
G
|
Wee1
|
WEE1 G2 checkpoint kinase
|
multiple interactions decreases expression
|
ISO
|
quizartinib promotes the reaction [RGFP966 results in decreased expression of WEE1 protein]; quizartinib promotes the reaction [romidepsin results in decreased expression of WEE1 protein]; RGFP966 promotes the reaction [quizartinib results in decreased expression of WEE1 protein]; romidepsin promotes the reaction [quizartinib results in decreased expression of WEE1 protein]
|
CTD |
PMID:34665271 |
|
NCBI chr 1:173,605,609...173,632,450
Ensembl chr 1:173,608,949...173,632,449
|
|